Verrica Pharmaceuticals Inc
VRCA4.390USD
+0.350+8.66%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
40.63MCap. mercado
PérdidaP/E TTM
Más Datos de Verrica Pharmaceuticals Inc Compañía
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Información de la empresa
Símbolo de cotizaciónVRCA
Nombre de la empresaVerrica Pharmaceuticals Inc
Fecha de salida a bolsaJun 15, 2018
Director ejecutivoDr. Jayson Rieger
Número de empleados71
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 15
Dirección44 West Gay Street
CiudadWEST CHESTER
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal19380
Teléfono14844533300
Sitio Webhttps://verrica.com/
Símbolo de cotizaciónVRCA
Fecha de salida a bolsaJun 15, 2018
Director ejecutivoDr. Jayson Rieger
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 15 de ago
Actualizado: vie., 15 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Manning (Paul B.)
52.73%
Caligan Partners, LP
9.78%
Armistice Capital LLC
9.40%
BKB Growth Investments LLC
6.33%
The Vanguard Group, Inc.
2.30%
Otro
19.47%
Accionistas
Accionistas
Proporción
Manning (Paul B.)
52.73%
Caligan Partners, LP
9.78%
Armistice Capital LLC
9.40%
BKB Growth Investments LLC
6.33%
The Vanguard Group, Inc.
2.30%
Otro
19.47%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
56.47%
Hedge Fund
20.50%
Corporation
6.60%
Investment Advisor
4.40%
Investment Advisor/Hedge Fund
1.20%
Research Firm
0.26%
Venture Capital
0.01%
Otro
10.55%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
183
8.91M
96.35%
+3.15M
2025Q1
194
69.94M
75.99%
+19.16M
2024Q4
191
70.39M
77.72%
+35.42M
2024Q3
179
29.67M
67.28%
-5.27M
2024Q2
173
33.68M
79.75%
-1.13M
2024Q1
171
34.51M
82.01%
-2.46M
2023Q4
170
35.04M
83.66%
+1.56M
2023Q3
172
32.74M
78.91%
-2.85M
2023Q2
169
31.35M
77.69%
+2.98M
2023Q1
171
29.74M
73.94%
+2.67M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Manning (Paul B.)
31.38M
33.93%
+17.53M
+126.54%
Nov 26, 2024
Caligan Partners, LP
8.99M
9.72%
+1.56M
+21.04%
Mar 31, 2025
Armistice Capital LLC
8.57M
9.26%
-353.60K
-3.96%
Mar 31, 2025
BKB Growth Investments LLC
5.98M
6.46%
+5.98M
--
Nov 22, 2024
The Vanguard Group, Inc.
2.36M
2.55%
+481.41K
+25.61%
Mar 31, 2025
Stalfort (John A)
1.87M
2.03%
+238.09K
+14.56%
Apr 01, 2025
Millennium Management LLC
395.65K
0.43%
+395.65K
--
Mar 31, 2025
Rieger (Jayson)
889.88K
0.96%
+300.19K
+50.91%
Apr 01, 2025
Sovran Advisors LLC
392.16K
0.42%
-14.89K
-3.66%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.02M
1.1%
+541.22K
+113.40%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
